Homo- and Heterodimerization of Proteins in Cell Signaling: Inhibition and Drug Design.

[1]  S. Sidhu,et al.  Engineering cell signaling modulators from native protein-protein interactions. , 2017, Current opinion in structural biology.

[2]  Yan Li,et al.  Ror2, a Developmentally Regulated Kinase, Is Associated With Tumor Growth, Apoptosis, Migration, and Invasion in Renal Cell Carcinoma. , 2017, Oncology research.

[3]  V. Iyer.  A Review of Stapled Peptides and Small Molecules to Inhibit Protein-Protein Interactions in Cancer. , 2016, Current Medicinal Chemistry.

[4]  D. Craik,et al.  Constrained Cyclic Peptides as Immunomodulatory Inhibitors of the CD2:CD58 Protein-Protein Interaction. , 2016, ACS chemical biology.

[5]  Daisuke Kihara,et al.  Prediction of homoprotein and heteroprotein complexes by protein docking and template‐based modeling: A CASP‐CAPRI experiment , 2016, Proteins.

[6]  K. Mineev,et al.  Structural Basis of p75 Transmembrane Domain Dimerization* , 2016, The Journal of Biological Chemistry.

[7]  J. Lanciego,et al.  Basic Pharmacological and Structural Evidence for Class A G-Protein-Coupled Receptor Heteromerization , 2016, Front. Pharmacol..

[8]  P. Medina,et al.  PD‐1 Pathway Inhibitors: Immuno‐Oncology Agents for Restoring Antitumor Immune Responses , 2016, Pharmacotherapy.

[9]  N. Gascoigne,et al.  Cell Type-Specific Regulation of Immunological Synapse Dynamics by B7 Ligand Recognition , 2016, Front. Immunol..

[10]  Jan Tavernier,et al.  Modulation of Protein–Protein Interactions for the Development of Novel Therapeutics , 2015, Molecular therapy : the journal of the American Society of Gene Therapy.

[11]  C. Ibáñez,et al.  Structural basis of death domain signaling in the p75 neurotrophin receptor , 2015, eLife.

[12]  S. Temtamy,et al.  Clinical and molecular characterization of seven Egyptian families with autosomal recessive robinow syndrome: Identification of four novel ROR2 gene mutations , 2015, American journal of medical genetics. Part A.

[13]  Edmond J. Breen,et al.  Linking structural features of protein complexes and biological function , 2015, Protein science : a publication of the Protein Society.

[14]  M. Kinjo,et al.  Homodimerization of glucocorticoid receptor from single cells investigated using fluorescence correlation spectroscopy and microwells , 2015, FEBS letters.

[15]  S. Jois,et al.  Surfing the Protein-Protein Interaction Surface Using Docking Methods: Application to the Design of PPI Inhibitors , 2015, Molecules.

[16]  Sashikanth Banappagari,et al.  Novel Peptidomimetics for Inhibition of HER2:HER3 Heterodimerization in HER2‐Positive Breast Cancer , 2015, Chemical biology & drug design.

[17]  T. Hünig,et al.  CD28 co-stimulation in T-cell homeostasis: a recent perspective , 2015, ImmunoTargets and therapy.

[18]  Dima Kozakov,et al.  The FTMap family of web servers for determining and characterizing ligand-binding hot spots of proteins , 2015, Nature Protocols.

[19]  Aaron M. Beedle,et al.  Inhibiting EGFR Dimerization Using Triazolyl-Bridged Dimerization Arm Mimics , 2015, PloS one.

[20]  Jeffrey M. Rosen,et al.  Ror2 regulates branching, differentiation, and actin-cytoskeletal dynamics within the mammary epithelium , 2015, The Journal of cell biology.

[21]  Simone Brogi,et al.  Discovery of GPCR ligands for probing signal transduction pathways , 2014, Front. Pharmacol..

[22]  D. Klimstra,et al.  EGFR, HER2 and HER3 dimerization patterns guide targeted inhibition in two histotypes of esophageal cancer , 2014, International journal of cancer.

[23]  Jicheng Duan,et al.  A New in Vivo Cross-linking Mass Spectrometry Platform to Define Protein–Protein Interactions in Living Cells* , 2014, Molecular & Cellular Proteomics.

[24]  J. Wells,et al.  Small-molecule inhibitors of protein-protein interactions: progressing toward the reality. , 2014, Chemistry & biology.

[25]  D. Sansom,et al.  Understanding the CD28/CTLA‐4 (CD152) Pathway and Its Implications for Costimulatory Blockade , 2014, American journal of transplantation : official journal of the American Society of Transplantation and the American Society of Transplant Surgeons.

[26]  R. Riek,et al.  Heterodimerization of p45–p75 Modulates p75 Signaling: Structural Basis and Mechanism of Action , 2014, PLoS biology.

[27]  S. Satyanarayanajois,et al.  Peptides and peptidomimetics as immunomodulators. , 2014, Immunotherapy.

[28]  Shilpa Gupta,et al.  PD-1 pathway inhibitors: changing the landscape of cancer immunotherapy. , 2014, Cancer control : journal of the Moffitt Cancer Center.

[29]  S. Satyanarayanajois,et al.  Structure-activity relationships of peptidomimetics that inhibit PPI of HER2-HER3. , 2014, Biopolymers.

[30]  Wenxing Guo,et al.  Hot spot-based design of small-molecule inhibitors for protein-protein interactions. , 2014, Bioorganic & medicinal chemistry letters.

[31]  A. Mark,et al.  Activation of the epidermal growth factor receptor: a series of twists and turns. , 2014, Biochemistry.

[32]  T. Golde,et al.  Complex Relationships between Substrate Sequence and Sensitivity to Alterations in γ-Secretase Processivity Induced by γ-Secretase Modulators , 2014, Biochemistry.

[33]  Kathryn S. Kennedy,et al.  Lifitegrast ophthalmic solution 5.0% for treatment of dry eye disease: results of the OPUS-1 phase 3 study. , 2014, Ophthalmology.

[34]  David Jou,et al.  Drug design targeting protein-protein interactions (PPIs) using multiple ligand simultaneous docking (MLSD) and drug repositioning: discovery of raloxifene and bazedoxifene as novel inhibitors of IL-6/GP130 interface. , 2014, Journal of medicinal chemistry.

[35]  Weiru Wang,et al.  Targeting protein-protein interaction by small molecules. , 2014, Annual review of pharmacology and toxicology.

[36]  H. Vié,et al.  Targeting CD28, CTLA-4 and PD-L1 Costimulation Differentially Controls Immune Synapses and Function of Human Regulatory and Conventional T-Cells , 2013, PloS one.

[37]  Nir London,et al.  Druggable protein-protein interactions--from hot spots to hot segments. , 2013, Current opinion in chemical biology.

[38]  J. Cidlowski,et al.  Glucocorticoid receptor signaling in health and disease. , 2013, Trends in pharmacological sciences.

[39]  David J Craik,et al.  Cyclotides as grafting frameworks for protein engineering and drug design applications. , 2013, Biopolymers.

[40]  L. Walker.  Treg and CTLA-4: Two intertwining pathways to immune tolerance , 2013, Journal of autoimmunity.

[41]  A. Costanzo,et al.  Treatment of Psoriasis and Psoriatic Arthritis , 2013, BioDrugs.

[42]  S. Satyanarayanajois,et al.  Immunosuppression by Co‐stimulatory Molecules: Inhibition of CD2‐CD48/CD58 Interaction by Peptides from CD2 to Suppress Progression of Collagen‐induced Arthritis in Mice , 2013, Chemical biology & drug design.

[43]  P. Gmeiner,et al.  Class A G-protein-coupled receptor (GPCR) dimers and bivalent ligands. , 2013, Journal of medicinal chemistry.

[44]  Harald Mauser,et al.  Design of Libraries Targeting Protein–Protein Interfaces , 2013, ChemMedChem.

[45]  Lieping Chen,et al.  Molecular mechanisms of T cell co-stimulation and co-inhibition , 2013, Nature Reviews Immunology.

[46]  P. Tang,et al.  Programmed Death 1 Pathway inhibition in Metastatic Renal Cell Cancer and Prostate Cancer , 2013, Current Oncology Reports.

[47]  D. Shaw,et al.  Conformational Coupling across the Plasma Membrane in Activation of the EGF Receptor , 2013, Cell.

[48]  Liping Xu,et al.  Heterobivalent ligands target cell-surface receptor combinations in vivo , 2012, Proceedings of the National Academy of Sciences.

[49]  L. Zitvogel,et al.  Targeting PD-1/PD-L1 interactions for cancer immunotherapy , 2012, Oncoimmunology.

[50]  G. Blancho,et al.  Preclinical Efficacy and Immunological Safety of FR104, an Antagonist Anti‐CD28 Monovalent Fab′ Antibody , 2012, American journal of transplantation : official journal of the American Society of Transplantation and the American Society of Transplant Surgeons.

[51]  Sashikanth Banappagari,et al.  Inhibition of protein–protein interaction of HER2–EGFR and HER2–HER3 by a rationally designed peptidomimetic , 2012, Journal of biomolecular structure & dynamics.

[52]  D. Scott,et al.  Fragment-based approaches in drug discovery and chemical biology. , 2012, Biochemistry.

[53]  L. S. Swapna,et al.  Extent of Structural Asymmetry in Homodimeric Proteins: Prevalence and Relevance , 2012, PloS one.

[54]  K. Papp,et al.  Biologic Therapy in Psoriasis: Perspectives on Associated Risks and Patient Management , 2012, Journal of cutaneous medicine and surgery.

[55]  Harry Jubb,et al.  Structural biology and drug discovery for protein-protein interactions. , 2012, Trends in pharmacological sciences.

[56]  Asher Mullard,et al.  Protein–protein interaction inhibitors get into the groove , 2012, Nature Reviews Drug Discovery.

[57]  O. Keskin,et al.  Transient protein-protein interactions. , 2011, Protein engineering, design & selection : PEDS.

[58]  Thomas Walz,et al.  Simultaneous visualization of the extracellular and cytoplasmic domains of the epidermal growth factor receptor , 2011, Nature Structural &Molecular Biology.

[59]  Ameya Gokhale,et al.  Conformationally constrained peptides from CD2 to modulate protein-protein interactions between CD2 and CD58. , 2011, Journal of medicinal chemistry.

[60]  P. Forgez,et al.  Glucocorticoid receptor and breast cancer , 2011, Breast Cancer Research and Treatment.

[61]  Sashikanth Banappagari,et al.  Structure-activity relationship of conformationally constrained peptidomimetics for antiproliferative activity in HER2-overexpressing breast cancer cell lines. , 2011, MedChemComm.

[62]  J. Javitch,et al.  Detection of antigen interactions ex vivo by proximity ligation assay: endogenous dopamine D2-adenosine A2A receptor complexes in the striatum. , 2011, BioTechniques.

[63]  M. Whitters,et al.  Selective CD28 Blockade Attenuates Acute and Chronic Rejection of Murine Cardiac Allografts in a CTLA‐4‐Dependent Manner , 2011, American journal of transplantation : official journal of the American Society of Transplantation and the American Society of Transplant Surgeons.

[64]  Philippe Roche,et al.  Chemical and structural lessons from recent successes in protein-protein interaction inhibition (2P2I). , 2011, Current opinion in chemical biology.

[65]  M. Ladanyi,et al.  New Strategies in Overcoming Acquired Resistance to Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitors in Lung Cancer , 2011, Clinical Cancer Research.

[66]  R. Hirose,et al.  Novel strategies in immunosuppression: issues in perspective. , 2011, Transplantation.

[67]  Eric O Long.  ICAM-1: Getting a Grip on Leukocyte Adhesion , 2011, The Journal of Immunology.

[68]  G. Blancho,et al.  A more selective costimulatory blockade of the CD28‐B7 pathway , 2011, Transplant international : official journal of the European Society for Organ Transplantation.

[69]  Robert H. Oakley,et al.  Cellular Processing of the Glucocorticoid Receptor Gene and Protein: New Mechanisms for Generating Tissue-specific Actions of Glucocorticoids* , 2010, The Journal of Biological Chemistry.

[70]  L. Aravind,et al.  The bridge-region of the Ku superfamily is an atypical zinc ribbon domain. , 2010, Journal of structural biology.

[71]  Sashikanth Banappagari,et al.  A Conformationally Constrained Peptidomimetic Binds to the Extracellular Region of HER2 Protein , 2010, Journal of biomolecular structure & dynamics.

[72]  O. Majdic,et al.  T cell stimulator cells, an efficient and versatile cellular system to assess the role of costimulatory ligands in the activation of human T cells , 2010, Journal of immunological methods.

[73]  N. Hayashi,et al.  The Bcl‐xL inhibitor, ABT‐737, efficiently induces apoptosis and suppresses growth of hepatoma cells in combination with sorafenib , 2010, Hepatology.

[74]  Shigeyuki Yokoyama,et al.  Structural Evidence for Loose Linkage between Ligand Binding and Kinase Activation in the Epidermal Growth Factor Receptor , 2010, Molecular and Cellular Biology.

[75]  Kam Y. J. Zhang,et al.  Clinical efficacy of a RAF inhibitor needs broad target blockade in BRAF-mutant melanoma , 2010, Nature.

[76]  B. Reif,et al.  Amyloid beta 42 peptide (Aβ42)-lowering compounds directly bind to Aβ and interfere with amyloid precursor protein (APP) transmembrane dimerization , 2010, Proceedings of the National Academy of Sciences.

[77]  Jonathan M. Green,et al.  An enigmatic tail of CD28 signaling. , 2010, Cold Spring Harbor perspectives in biology.

[78]  O. Bocharova,et al.  Spatial structure of the transmembrane domain heterodimer of ErbB1 and ErbB2 receptor tyrosine kinases. , 2010, Journal of molecular biology.

[79]  G. Marshall,et al.  Targeting the Dimerization of Epidermal Growth Factor Receptors with Small‐Molecule Inhibitors , 2010, Chemical biology & drug design.

[80]  S. Constantinescu,et al.  What is the role of amyloid precursor protein dimerization? , 2010, Cell adhesion & migration.

[81]  Thomas Singer,et al.  The safety and side effects of monoclonal antibodies , 2010, Nature Reviews Drug Discovery.

[82]  Andrew J. Wilson.  Inhibition of protein-protein interactions using designed molecules. , 2009, Chemical Society reviews.

[83]  R. Pierson,et al.  Inducing CTLA-4–Dependent Immune Regulation by Selective CD28 Blockade Promotes Regulatory T Cells in Organ Transplantation , 2010, Science Translational Medicine.

[84]  B. Strooper,et al.  The secretases: enzymes with therapeutic potential in Alzheimer disease , 2010, Nature Reviews Neurology.

[85]  Benjamin A. Shoemaker,et al.  Evolution of protein binding modes in homooligomers. , 2010, Journal of molecular biology.

[86]  S. Satyanarayanajois,et al.  Design, Synthesis, and Docking Studies of Peptidomimetics Based on HER2–Herceptin Binding Site with Potential Antiproliferative Activity Against Breast Cancer Cell lines , 2009, Chemical biology & drug design.

[87]  F. Cappuzzo,et al.  Predictive value of EGFR and HER2 overexpression in advanced non-small-cell lung cancer , 2009, Oncogene.

[88]  Brea Midthune,et al.  Induced Dimerization of the Amyloid Precursor Protein Leads to Decreased Amyloid-β Protein Production* , 2009, The Journal of Biological Chemistry.

[89]  J. Baselga,et al.  Novel anticancer targets: revisiting ERBB2 and discovering ERBB3 , 2009, Nature Reviews Cancer.

[90]  Markus H. J. Seifert,et al.  Natural product inhibitors of protein-protein interactions mediated by Src-family SH2 domains. , 2009, Bioorganic & medicinal chemistry letters.

[91]  J. Caldwell,et al.  Lipid G Protein-coupled Receptor Ligand Identification Using β-Arrestin PathHunter™ Assay , 2009, Journal of Biological Chemistry.

[92]  P. Linsley,et al.  The clinical utility of inhibiting CD28‐mediated costimulation , 2009, Immunological reviews.

[93]  A. Sharpe.  Mechanisms of costimulation , 2009, Immunological reviews.

[94]  H. Schneider,et al.  CD28 and CTLA‐4 coreceptor expression and signal transduction , 2009, Immunological reviews.

[95]  J. Russell,et al.  Targeted Knock-In Mice Expressing Mutations of CD28 Reveal an Essential Pathway for Costimulation , 2009, Molecular and Cellular Biology.

[96]  S. Constantinescu,et al.  A helix-to-coil transition at the ε-cut site in the transmembrane dimer of the amyloid precursor protein is required for proteolysis , 2009, Proceedings of the National Academy of Sciences.

[97]  I. McLay,et al.  The first X-ray crystal structure of the glucocorticoid receptor bound to a non-steroidal agonist. , 2008, Bioorganic & medicinal chemistry letters.

[98]  I. Maruyama,et al.  All EGF(ErbB) receptors have preformed homo- and heterodimeric structures in living cells , 2008, Journal of Cell Science.

[99]  T. Walz,et al.  Functional and structural stability of the epidermal growth factor receptor in detergent micelles and phospholipid nanodiscs. , 2008, Biochemistry.

[100]  S. Almo,et al.  Crystal structure of the complex between programmed death-1 (PD-1) and its ligand PD-L2 , 2008, Proceedings of the National Academy of Sciences.

[101]  G. Freeman,et al.  Structures of PD-1 with its ligands: Sideways and dancing cheek to cheek , 2008, Proceedings of the National Academy of Sciences.

[102]  M. Sliwkowski,et al.  A central role for HER3 in HER2-amplified breast cancer: implications for targeted therapy. , 2008, Cancer research.

[103]  Lorenz M Mayr,et al.  The Future of High-Throughput Screening , 2008, Journal of biomolecular screening.

[104]  Hyeong Jun An,et al.  Estimating the size of the human interactome , 2008, Proceedings of the National Academy of Sciences.

[105]  K. Ferguson,et al.  Structure-based view of epidermal growth factor receptor regulation. , 2008, Annual review of biophysics.

[106]  L. Hunyady,et al.  Dimerization and oligomerization of G-protein-coupled receptors: debated structures with established and emerging functions. , 2008, The Journal of endocrinology.

[107]  D. Y. Lin,et al.  The PD-1/PD-L1 complex resembles the antigen-binding Fv domains of antibodies and T cell receptors , 2008, Proceedings of the National Academy of Sciences.

[108]  Christopher L. McClendon,et al.  Reaching for high-hanging fruit in drug discovery at protein–protein interfaces , 2007, Nature.

[109]  Yan Liu,et al.  Homodimerization of Ror2 tyrosine kinase receptor induces 14-3-3(beta) phosphorylation and promotes osteoblast differentiation and bone formation. , 2007, Molecular endocrinology.

[110]  J. Mallol,et al.  Basic Concepts in G-Protein-Coupled Receptor Homo- and Heterodimerization , 2007, TheScientificWorldJournal.

[111]  R. Mariuzza,et al.  Structure of natural killer receptor 2B4 bound to CD48 reveals basis for heterophilic recognition in signaling lymphocyte activation molecule family. , 2007, Immunity.

[112]  J. Allison,et al.  The B7 Family and Cancer Therapy: Costimulation and Coinhibition , 2007, Clinical Cancer Research.

[113]  Pedro A Fernandes,et al.  Hot spots—A review of the protein–protein interface determinant amino‐acid residues , 2007, Proteins.

[114]  D. Biskobing.  Update on bazedoxifene: A novel selective estrogen receptor modulator , 2007, Clinical interventions in aging.

[115]  C. Almeida,et al.  Internalized Antibodies to the Aβ Domain of APP Reduce Neuronal Aβ and Protect against Synaptic Alterations*♦ , 2007, Journal of Biological Chemistry.

[116]  M. Åkesson,et al.  Discovery of Selective Small-Molecule CD80 Inhibitors , 2007, Journal of biomolecular screening.

[117]  Dieter Langosch,et al.  GxxxG motifs within the amyloid precursor protein transmembrane sequence are critical for the etiology of Aβ42 , 2007 .

[118]  G. Freeman,et al.  The function of programmed cell death 1 and its ligands in regulating autoimmunity and infection , 2007, Nature Immunology.

[119]  D. Erlanson.  Fragment-based lead discovery: a chemical update. , 2006, Current opinion in biotechnology.

[120]  Andrea Iaboni,et al.  A rigorous experimental framework for detecting protein oligomerization using bioluminescence resonance energy transfer , 2006, Nature Methods.

[121]  Sarah A. Teichmann,et al.  3D Complex: A Structural Classification of Protein Complexes , 2006, PLoS Comput. Biol..

[122]  Sandra Fox,et al.  High-Throughput Screening: Update on Practices and Success , 2006, Journal of biomolecular screening.

[123]  Lindzy D. Friend,et al.  A dose-dependent requirement for the proline motif of CD28 in cellular and humoral immunity revealed by a targeted knockin mutant , 2006, The Journal of experimental medicine.

[124]  Edgar Jacoby,et al.  The 7 TM G‐Protein‐Coupled Receptor Target Family , 2006, ChemMedChem.

[125]  David W. Russell,et al.  Identification of associated proteins by coimmunoprecipitation. , 2006, CSH protocols.

[126]  Haluk Resat,et al.  Modeling the effects of HER/ErbB1-3 coexpression on receptor dimerization and biological response. , 2006, Biophysical journal.

[127]  G. Wiederschain.  Protein-protein interactions. A molecular cloning manual , 2006, Biochemistry (Moscow).

[128]  S. Constantinescu,et al.  Inhibitors of amyloid toxicity based on beta-sheet packing of Abeta40 and Abeta42. , 2006, Biochemistry.

[129]  P. Chène,et al.  Drugs Targeting Protein–Protein Interactions , 2006, ChemMedChem.

[130]  J. Goodrich,et al.  Protein-protein interaction assays: eliminating false positive interactions , 2006, Nature Methods.

[131]  T. Karpova,et al.  Detecting Protein–Protein Interactions with CFP‐YFP FRET by Acceptor Photobleaching , 2006, Current protocols in cytometry.

[132]  M. Dowsett,et al.  Trastuzumab after adjuvant chemotherapy in HER2-positive breast cancer. , 2005, The New England journal of medicine.

[133]  R. Paro,et al.  Homo‐ and heterodimerization of APP family members promotes intercellular adhesion , 2005, The EMBO journal.

[134]  D. V. Van Vranken,et al.  Binding of madindoline A to the extracellular domain of gp130. , 2005, Biochemistry.

[135]  Cui Zhanhua,et al.  Protein subunit interfaces: heterodimers versus homodimers , 2005, Bioinformation.

[136]  S. Korsmeyer,et al.  An inhibitor of Bcl-2 family proteins induces regression of solid tumours , 2005, Nature.

[137]  J. Tyndall,et al.  GPCR agonists and antagonists in the clinic. , 2005, Medicinal chemistry (Shariqah (United Arab Emirates)).

[138]  P. Linsley,et al.  Rational Development of LEA29Y (belatacept), a High‐Affinity Variant of CTLA4‐Ig with Potent Immunosuppressive Properties , 2005, American journal of transplantation : official journal of the American Society of Transplantation and the American Society of Transplant Surgeons.

[139]  K. Wittkowski,et al.  Alefacept reduces infiltrating T cells, activated dendritic cells, and inflammatory genes in psoriasis vulgaris. , 2005, Proceedings of the National Academy of Sciences of the United States of America.

[140]  T. Berg.  Methods in Molecular Biology Vol. 261: Protein–Protein Interactions: Methods and Applications. Edited by Haian Fu. , 2005 .

[141]  T. Willnow,et al.  p75NTR – live or let die , 2005, Current Opinion in Neurobiology.

[142]  Gideon Schreiber,et al.  The molecular architecture of protein-protein binding sites. , 2005, Current opinion in structural biology.

[143]  I. Ispolatov,et al.  Binding properties and evolution of homodimers in protein–protein interaction networks , 2005, Nucleic acids research.

[144]  J. Matthews,et al.  The power of two: protein dimerization in biology. , 2004, Trends in biochemical sciences.

[145]  K. Ferguson.  Active and inactive conformations of the epidermal growth factor receptor. , 2004, Biochemical Society transactions.

[146]  Gary J. Jenkins,et al.  Ubiquitination and Degradation of Neuronal Nitric-Oxide Synthase in Vitro: Dimer Stabilization Protects the Enzyme from Proteolysis , 2004, Molecular Pharmacology.

[147]  B. Carter,et al.  A Functional Interaction between the p75 Neurotrophin Receptor Interacting Factors, TRAF6 and NRIF* , 2004, Journal of Biological Chemistry.

[148]  Michael Cammer,et al.  Structural and functional analysis of the costimulatory receptor programmed death-1. , 2004, Immunity.

[149]  L. Vassilev,et al.  In Vivo Activation of the p53 Pathway by Small-Molecule Antagonists of MDM2 , 2004, Science.

[150]  Simon J Davis,et al.  Molecular interactions mediating T cell antigen recognition. , 2003, Annual review of immunology.

[151]  H. Saibil,et al.  Arachnology: Scavenging by brown recluse spiders , 2003, Nature.

[152]  M. Sliwkowski,et al.  An open-and-shut case? Recent insights into the activation of EGF/ErbB receptors. , 2003, Molecular cell.

[153]  J. Allison,et al.  BTLA is a lymphocyte inhibitory receptor with similarities to CTLA-4 and PD-1 , 2003, Nature Immunology.

[154]  H. Schiöth,et al.  The G-protein-coupled receptors in the human genome form five main families. Phylogenetic analysis, paralogon groups, and fingerprints. , 2003, Molecular pharmacology.

[155]  R. Schwartz.  T cell anergy. , 2003, Annual review of immunology.

[156]  Michelle R Arkin,et al.  Discovery of a potent small molecule IL-2 inhibitor through fragment assembly. , 2003, Journal of the American Chemical Society.

[157]  P. Anton van der Merwe,et al.  The nature of molecular recognition by T cells , 2003, Nature Immunology.

[158]  A. M. Stanley,et al.  Structure of the extracellular region of HER 2 alone and in complex with the Herceptin Fab , 2022 .

[159]  G. Freeman,et al.  Blockade of Programmed Death-1 Ligands on Dendritic Cells Enhances T Cell Activation and Cytokine Production 1 , 2003, The Journal of Immunology.

[160]  Hyun-soo Cho,et al.  EGF activates its receptor by removing interactions that autoinhibit ectodomain dimerization. , 2003, Molecular cell.

[161]  M. Sliwkowski,et al.  Structure of the Epidermal Growth Factor Receptor Kinase Domain Alone and in Complex with a 4-Anilinoquinazoline Inhibitor* , 2002, The Journal of Biological Chemistry.

[162]  Jae-Hoon Kim,et al.  Crystal Structure of the Complex of Human Epidermal Growth Factor and Receptor Extracellular Domains , 2002, Cell.

[163]  Edouard C. Nice,et al.  Crystal Structure of a Truncated Epidermal Growth Factor Receptor Extracellular Domain Bound to Transforming Growth Factor α , 2002, Cell.

[164]  T. Willson,et al.  Crystal Structure of the Glucocorticoid Receptor Ligand Binding Domain Reveals a Novel Mode of Receptor Dimerization and Coactivator Recognition , 2002, Cell.

[165]  J. Janin,et al.  Dissecting protein–protein recognition sites , 2002, Proteins.

[166]  U. Landegren,et al.  Protein detection using proximity-dependent DNA ligation assays , 2002, Nature Biotechnology.

[167]  Yen-Ming Hsu,et al.  Alefacept, an Immunomodulatory Recombinant LFA-3/IgG1 Fusion Protein, Induces CD16 Signaling and CD2/CD16-Dependent Apoptosis of CD2+ Cells1 , 2002, The Journal of Immunology.

[168]  W. David Wilson,et al.  Analyzing Biomolecular Interactions , 2002, Science.

[169]  W. Delano.  Unraveling hot spots in binding interfaces: progress and challenges. , 2002, Current opinion in structural biology.

[170]  E. Nogales,et al.  Refined structure of alpha beta-tubulin at 3.5 A resolution. , 2001, Journal of molecular biology.

[171]  E. Reinherz,et al.  Molecular dissection of the CD2-CD58 counter-receptor interface identifies CD2 Tyr86 and CD58 Lys34 residues as the functional "hot spot". , 2001, Journal of molecular biology.

[172]  T. Bayer,et al.  Homodimerization of Amyloid Precursor Protein and Its Implication in the Amyloidogenic Pathway of Alzheimer's Disease* , 2001, The Journal of Biological Chemistry.

[173]  A. Hölscher,et al.  Epidermal growth factor receptor and HER2-neu mRNA expression in non-small cell lung cancer Is correlated with survival. , 2001, Clinical cancer research : an official journal of the American Association for Cancer Research.

[174]  Michel Bouvier,et al.  Oligomerization of G-protein-coupled transmitter receptors , 2001, Nature Reviews Neuroscience.

[175]  K. Sakamaki,et al.  Identification and characterization of rat AILIM/ICOS, a novel T-cell costimulatory molecule, related to the CD28/CTLA4 family. , 2000, Biochemical and biophysical research communications.

[176]  A J Olson,et al.  Structural symmetry and protein function. , 2000, Annual review of biophysics and biomolecular structure.

[177]  J. Treanor,et al.  Beta-secretase cleavage of Alzheimer's amyloid precursor protein by the transmembrane aspartic protease BACE. , 1999, Science.

[178]  Gerhard Wagner,et al.  Structure of a Heterophilic Adhesion Complex between the Human CD2 and CD58 (LFA-3) Counterreceptors , 1999, Cell.

[179]  C. Chothia,et al.  The atomic structure of protein-protein recognition sites. , 1999, Journal of molecular biology.

[180]  P. Bretscher,et al.  A two-step, two-signal model for the primary activation of precursor helper T cells. , 1999, Proceedings of the National Academy of Sciences of the United States of America.

[181]  A. Bogan,et al.  Anatomy of hot spots in protein interfaces. , 1998, Journal of molecular biology.

[182]  D. Thorley-Lawson,et al.  A ligand for human CD48 on epithelial cells. , 1997, Journal of Immunology.

[183]  G. Powers,et al.  Identification of a Small Molecule Inhibitor of the IL-2/IL-2Rα Receptor Interaction Which Binds to IL-2 , 1997 .

[184]  P. Hajduk,et al.  Discovering High-Affinity Ligands for Proteins: SAR by NMR , 1996, Science.

[185]  T. Clackson,et al.  A hot spot of binding energy in a hormone-receptor interface , 1995, Science.

[186]  T. Honjo,et al.  Induced expression of PD‐1, a novel member of the immunoglobulin gene superfamily, upon programmed cell death. , 1992, The EMBO journal.

[187]  Wim G. J. Hol,et al.  In search of new lead compounds for trypanosomiasis drug design: A protein structure-based linked-fragment approach , 1992, J. Comput. Aided Mol. Des..

[188]  C. Masters,et al.  Amyloid plaque core protein in Alzheimer disease and Down syndrome. , 1985, Proceedings of the National Academy of Sciences of the United States of America.

[189]  C. D. Jones,et al.  Antiestrogens. 2. Structure-activity studies in a series of 3-aroyl-2-arylbenzo[b]thiophene derivatives leading to [6-hydroxy-2-(4-hydroxyphenyl)benzo[b]thien-3-yl] [4-[2-(1-piperidinyl)ethoxy]-phenyl]methanone hydrochloride (LY156758), a remarkably effective estrogen antagonist with only minimal in , 1984, Journal of medicinal chemistry.

[190]  W. Jencks,et al.  On the attribution and additivity of binding energies. , 1981, Proceedings of the National Academy of Sciences of the United States of America.

[191]  Françoise Ochsenbein,et al.  Targeting protein–protein interactions, a wide open field for drug design , 2016 .

[192]  T. Dudnakova,et al.  Methods Molecular Biology , 2016 .

[193]  E. Buchbinder,et al.  CTLA-4 and PD-1 Pathways , 2016, American Journal of Clinical Oncology.

[194]  M. Skwarczynska,et al.  Protein-protein interactions as drug targets. , 2015, Future medicinal chemistry.

[195]  J. Treanor,et al.  Title beta-secretase cleavage of Alzheimer ' s amyloid precursor protein by the transmembrane aspartic protease , 2015 .

[196]  F. Hirsch,et al.  Quality of care of patients with non-small-cell lung cancer: a report of a performance improvement initiative. , 2014, Cancer control : journal of the Moffitt Cancer Center.

[197]  M. Ford,et al.  Targeting co-stimulatory pathways: transplantation and autoimmunity , 2014, Nature Reviews Nephrology.

[198]  R. Roskoski.  The ErbB/HER family of protein-tyrosine kinases and cancer. , 2014, Pharmacological research.

[199]  K. Pfleger,et al.  Study of GPCR-protein interactions by BRET. , 2011, Methods in molecular biology.

[200]  M. Khrestchatisky,et al.  Synthetic therapeutic peptides: science and market. , 2010, Drug discovery today.

[201]  M. Fischer,et al.  Surface plasmon resonance: a general introduction. , 2010, Methods in molecular biology.

[202]  T. Hünig.  Manipulation of regulatory T-cell number and function with CD28-specific monoclonal antibodies. , 2007, Advances in immunology.

[203]  C. Almeida,et al.  Internalized antibodies to the Abeta domain of APP reduce neuronal Abeta and protect against synaptic alterations. , 2007, The Journal of biological chemistry.

[204]  L. Luttrell.  Transmembrane signaling by G protein-coupled receptors. , 2006, Methods in molecular biology.

[205]  R. A. Hall,et al.  CO-IMMUNOPRECIPITATION AS A STRATEGY TO EVALUATE RECEPTOR-RECEPTOR OR RECEPTOR-PROTEIN INTERACTIONS , 2005 .

[206]  G. Freeman,et al.  The B7 family revisited. , 2005, Annual review of immunology.

[207]  A. Velázquez‐Campoy,et al.  Characterization of protein-protein interactions by isothermal titration calorimetry. , 2004, Methods in molecular biology.

[208]  H. Saibil,et al.  Biophysics: is rhodopsin dimeric in native retinal rods? , 2003, Nature.

[209]  W. Wilson.  Tech.Sight. Analyzing biomolecular interactions. , 2002, Science.

[210]  Yves-Alain Barde,et al.  The neurotrophin receptor p75(NTR): novel functions and implications for diseases of the nervous system. , 2002, Nature neuroscience.